RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can taking a cancer drug less often reduce side effects?
Disease control OngoingThis study tests whether giving duvelisib on an irregular schedule can still control chronic lymphocytic leukemia or small lymphocytic lymphoma while causing fewer severe side effects. Fifteen adults with cancer that has come back or not responded to treatment will take part. The…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 04:19 UTC
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment where a patient's own immune cells are modified in a lab to recognize and attack a protein called CD20 on cancer cells. It is for people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has returned or not responded to prior thera…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
Two-Drug combo shows promise against Hard-to-Treat leukemia
Disease control OngoingThis study tested a combination of two targeted drugs, venetoclax and ibrutinib, in 234 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal was to see how well the drugs control the cancer, especially in patients whose disease came back or had h…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 03:56 UTC
-
Engineered t cells take on returning B-Cell cancers in early trial
Disease control OngoingThis early-phase study tests a new treatment for adults with B-cell cancers (like lymphoma or leukemia) that returned after prior therapy. Doctors take a patient's own white blood cells, add a gene to help them find and kill cancer cells, and give them back after chemotherapy. Th…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:04 UTC
-
New combo tested for relapsed leukemia: does adding rituximab help?
Disease control OngoingThis study tests whether adding rituximab to ibrutinib works better than ibrutinib alone for patients with chronic lymphocytic leukemia (CLL) that has returned after treatment. About 66 adults with relapsed CLL or related blood cancers will receive either ibrutinib alone or ibrut…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
Engineered immune cells take aim at Tough-to-Treat blood cancers
Disease control OngoingThis early-stage trial is testing a new type of immunotherapy for people with certain blood cancers (like lymphoma and leukemia) that have returned or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recogn…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo therapy shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis early-phase study tests a combination of three drugs (lenalidomide, ibrutinib, and rituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatment. The main goal is to find the safest dose…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
New combo tackles tough blood cancers
Disease control OngoingThis early-phase study tests two drugs, pevonedistat and ibrutinib, together in people with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma that has returned or no longer responds to standard therapy. The main goal is to find the safest dose and understand side effects…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 04, 2026 16:32 UTC